Granisetron.HCL: Leading Solution for Nausea & Vomiting in Cancer Treatments
ProcurenetShort description
Granisetron.HCL: Effective Solution for Nausea & Vomiting in Cancer Therapies
Granisetron.HCL is a top-tier pharmaceutical primarily used to mitigate nausea and vomiting reactions associated with radiation and chemotherapy. This 5-HT3 antagonist, frequently prescribed for cancer patients, is produced in strict observance of high-quality standards.
- CAS Number: 107007-99-8
- Chemical Formula: C18H24N4O•HCl
- Perfectly tailored for global markets
- Adherence to stringent GMP guidelines ensures safety and quality
- A high yield of 50 kg/month
- Eco-conscious packaging: 10 kg/drum
-
Procurenet Team Tshim Sha Tsui
Hong Kong
3 years
Description
Granisetron.HCL: Effective Solution for Nausea & Vomiting in Cancer Therapies
Granisetron.HCL, a pharmaceutical-grade compound with the CAS Number 107007-99-8, offers an effective solution for nausea and vomiting - distressing side-effects often seen in patients undergoing radiation therapy or chemotherapy for cancer treatment. Its primary function is to serve as an antagonist of 5-HT3 serotonin receptors in the peripheral vagus nerve endings and centrally in the chemoreceptor trigger zone. Its high efficacy makes it a trusted aid in cancer therapy, benefiting patient comfort and wellbeing worldwide.
Key Features:
- Pharmaceutical-Grade Compound: Granisetron.HCL is a premium quality pharmaceutical-grade compound, ensuring safety and effectiveness.
- Wide-Spread Use: It finds applications globally, including regions such as North America, Central and South America, Western and Eastern Europe, Australasia, Asia, Middle East, and Africa.
- Consistent Supply: With a stable monthly production capacity of 50kg, it guarantees uninterrupted supply.
- Packaging: The 10kg per drum packaging protects the product quality during transit.
Special Therapeutic Benefits:
Granisetron HCL is renowned for its exceptional therapeutic benefits in controlling nausea and vomiting induced by chemotherapy and radiation therapy in cancer patients. Its selectivity in blocking 5-HT3 receptors significantly reduces these common side-effects, enhancing the quality of life for patients during such distressful times. However, dosage and usage must be directed and continuously monitored by a healthcare professional to manage and mitigate potential side-effects and drug interactions.
Select Granisetron.HCL for its superior safety profile and effectiveness in combating radiation and chemotherapy-induced nausea and vomiting. Its unique benefits make it a reliable companion in the mitigation of cancer therapy's adverse effects. On the journey towards recovery, trust Granisetron.HCL for comfort and care.
